Eli Lilly and Company

For nearly 150 years, we’ve made significant and game-changing progress on our mission to make life better for people around the world. We’ve remained headquartered in Indianapolis, Indiana, since our founding on May 10, 1876, but our employees now work in countries around the world.

And thanks to the dedication of our diverse global team, we’ve been able to answer the call for new medicines to help solve some of the world’s most significant health challenges

When you’re on a mission to do what’s never been done before, you seek people willing to challenge the status quo of medicine. Those willing to relentlessly pursue what’s next, all in the name of health above all. #WeAreLilly

  • 2026 - Best Places to Work - Badge (1).png
  • 2025 BPTW Badge - RBG.png
  • 2024 Best Places to Work
  • 2023 Best Places to Work
  • 2022 Best Places to Work
893 S Delaware St
Indianapolis, IN 46285
  • Featured Employer
Hard work, Selfless purpose. Urgent impact.
Make a difference that matters.
We are Lilly
Why do our employees love coming to work each and every day? Here’s what they have to say.
  • “Opportunity for growth is actually the biggest reason that I ended up hiring into Lilly.”
    Kavita - Associate Director, Packaging Operations
  • “Lilly worked very hard to be able to allow me to settle into my role, but they also had a great deal of consideration for my life outside of work.”
    Adrian - Associate Director, Manufacturing & Quality
  • “What we do matters, it matters to the people that we interact with. It matters to people in our families and it matters to people around the world.”
    Cecile - Sr Director, Design Hub Foundations
47,000 global employees coming together from diverse backgrounds to create medicines that make life better for people around the world. Get to know Team Lilly through our Powered by Purpose series.
NEWS
Biotech and pharma companies strengthen their leadership teams with new appointments.
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops and commercializes high quality medicines, presented the research data on the treatment of relapsed or refractory extranodal NK/T cell lymphoma with sintilimab, co-developed with Eli Lilly and Company and key data from six other clinical studies were presented at the 55th Annual Meeting of the American Society of Clinical Oncology by oral presentation and posters.
FDA
As fireworks illuminate the night skies across the United States this weekend in celebration of Independence Day, BioSpace takes a look at some of the highlights of the pharma industry from the first half of 2019 and earlier that provides millions of patients with the independence of health.
According to a BioSpace poll, over half (56%) of respondents are not happy with their current life sciences position. Are you one of the 56%? You deserve to be happy! Start working towards your happiness and check out job opportunities at these top companies!
Exiting the last week of June and heading into July, a number of companies announced results from ongoing clinical trials. Here’s a look.
The lawsuit was joined by Merck, Eli Lilly and Amgen. The companies claim the Department of Health and Human Services does not have the legal authority to force the companies to comply with the new rule.
Last week there were quite a few clinical trials whose data were presented. Many were at the American Diabetes Association 79th Scientific Sessions, while others were presented at separate meetings or independently. Here’s a look.
Almost 15,000 physicians, scientists, health care professionals and industry representatives from around the globe presented research, treatment recommendations and advances toward a diabetes cure at the American Diabetes Association’s 79th Scientific Sessions in San Francisco this week.
Despite very positive results, the company’s shares were down 1.5% in premarket trading today. Vamil Divan, an analyst with Credite Suisse, wrote in a note to investors, that results “were fairly consistent across various patient subgroups and are clearly positive” for this class of drug, but “we believe investors may have been hoping for greater risk reduction.”
JOBS
IN THE PRESS